<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800357</url>
  </required_header>
  <id_info>
    <org_study_id>xijing-007</org_study_id>
    <nct_id>NCT01800357</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Mildronate for Acute Ischemic Stroke</brief_title>
  <official_title>Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the efficacy and safety of mildronate injection in treating
      acute ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a randomized, double-blind, placebo-controlled phase II multicenter trial is conducted to
      evaluate the efficacy and safety of mildronate injection in patients with acute ischemic
      stroke. patients will be randomized to receive a 14-day treatment of placebo or mildronate
      (500mg/5ml/each).Primary end-point is the modified Rankin scale at 3 monthes. Secondary
      end-point is the NIHSS scores and the Barthel index at 8 days and 15days. The safety
      end-point is defined as the incidence of adverse events, the change of Samples for routine
      laboratory tests and vital signs. Analysis is by intention to treat.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the modified Rankin scale</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS scores</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS scores</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Barthel index</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Barthel index</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>mildronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of mildronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>infusion of placebo mildronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infusion of mildronate</intervention_name>
    <description>infusion of mildronate(500mg) once a day and for 14 days</description>
    <arm_group_label>mildronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>infusion of plabcebo once a day and for 14 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>infusion of aspirin (100mg) once a day for days</description>
    <arm_group_label>mildronate</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - have a clinical diagnosis of acute ischemic stroke have CT or MRI brain imaging NIHSS
        scores:5~22 on the first stage

        Exclusion Criteria:

        - have other intracranial pathologies are pregnant or nursing have significant drug or
        alcohol misuse have been in a clinical trial in the past 3 months are unlikely to be
        available for follow-up have been given thrombolytic therapy or medication forbidden by
        study protocol have a neurological or psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>the Department of Neurology , Xijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Zhu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>the Department of Neurology , Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Zhao, MD</last_name>
    <phone>02984775361</phone>
    <email>zhaogang@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Department of Neurology , Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Zhao, MD</last_name>
      <phone>02984775361</phone>
      <email>zhaogang@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yi Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guang Yun Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized trial</keyword>
  <keyword>acute ischemic stroke</keyword>
  <keyword>mildronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>3-(2,2,2-trimethylhydrazine)propionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

